Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Curtis Rosebraugh"'
Autor:
Amy Egan, Kristina Dunder, Curtis Rosebraugh, B. Timothy Hummer, Pieter A. de Graeff, Todd Bourcier, Eberhard Blind
Publikováno v:
New England Journal of Medicine, 370(9), 794-797. MASSACHUSETTS MEDICAL SOC
After evaluating a safety signal regarding pancreatitis and pancreatic cancer in patients using incretin-based drugs, the Food and Drug Administration and the European Medicines Agency conclude that assertions of a causal association are inconsistent
Publikováno v:
New England Journal of Medicine. 367:1577-1579
After weighing the risks and benefits, the FDA recently approved two new drugs as adjuncts to a reduced-calorie diet and increased physical activity for chronic weight management in obese or overweight adults with at least one weight-related coexisti
Autor:
Yi Tsong, Min Chen, Feng Zhou, David A. Flockhart, Denise Toyer, Curtis Rosebraugh, Charlene M. Flowers, Ann Corken Mackey, Peter K. Honig
Publikováno v:
Pharmacoepidemiology and Drug Safety. 12:97-101
Purpose Evaluate whether a 15-minute lecture intervention will improve adverse drug reaction reporting quality on standard MedWatch forms. Methods Seventy-eight 4th-year medical students were randomized to intervention ‘Group-A’ or non-interventi
Publikováno v:
Clinical Pharmacology & Therapeutics. 71:4-10
Autor:
Curtis Rosebraugh, Mary H. Parks
Publikováno v:
The New England journal of medicine. 362(9)
On January 25, the FDA approved liraglutide, a glucagon-like-peptide-1 receptor agonist that can improve glycemic control in adults with type 2 diabetes. Drs. Mary Parks and Curtis Rosebraugh discuss the benefits and potentially serious safety concer